

# CITATION REPORT

List of articles citing

**Insulin resistance: a metabolic pathway to chronic liver disease**

**DOI: 10.1002/hep.20920**  
**Hepatology, 2005, 42, 987-1000.**

**Source:** <https://exaly.com/paper-pdf/38330051/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
665	Impact of insulin resistance on the progression of chronic liver diseases. <b>1998</b> , 22, 801		
664	Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. <b>2005</b> , 22, 330-8		77
663	The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , <b>2006</b> , 55, 1604-9	12.7	93
662	The status of liver transplantation for hepatitis C. <b>2006</b> , 6, 993-1002		1
661	A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. <b>2006</b> , 169, 846-60		221
660	Esteatosis hepática y resistencia a la insulina: ¿qu¿ ocurre primero?. <b>2006</b> , 18, 72-82		
659	The evolving role of leptin and adiponectin in chronic liver diseases. <b>2006</b> , 101, 2629-40		145
658	Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. <b>2006</b> , 4, 1162-9		58
657	PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling. <b>2006</b> , 112, 89-104		69
656	Non-alcoholic fatty liver disease: current concepts and management strategies. <b>2006</b> , 6, 19-25		116
655	Profile of rhythmic gene expression in the livers of obese diabetic KK-A(y) mice. <b>2006</b> , 346, 1297-302		38
654	'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. <b>2006</b> , 44, 1196-207		97
653	Insulin resistance and HCV: will new knowledge modify clinical management?. <b>2006</b> , 45, 514-9		44
652	Current World Literature. <b>2006</b> , 11, 311-350		
651	Non-alcoholic steatohepatitis and metabolic syndrome. <b>2006</b> , 9, 637-42		78
650	The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. <b>2006</b> , 6, 33		1135
649	Unexplained CK elevations in patients with nonalcoholic steatohepatitis. <b>2006</b> , 26, 899-900		2

648	Role of Kupffer cells in host defense and liver disease. <b>2006</b> , 26, 1175-86		568
647	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <b>2006</b> , 24, 1215-22		80
646	Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. <b>2006</b> , 24, 1553-61		132
645	Histological assessment of non-alcoholic fatty liver disease. <b>2006</b> , 49, 450-65		210
644	Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. <b>2006</b> , 7, 627-33		25
643	Hépatopathie non alcoolique: de la stéatose à la cirrhose. <b>2006</b> , 36, 299-314		1
642	Nonalcoholic fatty liver disease and HIV infection. <b>2006</b> , 3, 113-7		7
641	Correlation between insulin resistance and hepatitis C viral load. <i>Hepatology</i> , <b>2006</b> , 43, 1168; author reply 1168-9	11.2	43
640	Reply:. <i>Hepatology</i> , <b>2006</b> , 43, 1167-1168	11.2	2
639	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. <i>Hepatology</i> , <b>2006</b> , 44, 1648-55	11.2	126
638	Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: a preliminary study. <b>2006</b> , 91, 2279-85		18
637	Definitions of metabolic syndrome: Where are we now?. <b>2006</b> , 4, 185-97		31
636	Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. <b>2006</b> , 291, E282-90		124
635	A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. <b>2007</b> , 60, 1384-91		18
634	Pathology of nonalcoholic fatty liver disease. <b>2007</b> , 128, 837-47		229
633	Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. <b>2007</b> , 282, 27141-27154		156
632	Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. <b>2007</b> , 30, 2638-40		98
631	Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. <b>2007</b> , 30, 1819-27		74

- 630 A Thr94Ala mutation in human liver fatty acid-binding protein contributes to reduced hepatic glycogenolysis and blunted elevation of plasma glucose levels in lipid-exposed subjects. **2007**, 293, E1078-84 40
- 629 Carbohydrate metabolism and the liver: actual aspects from physiology and disease. **2007**, 45, 51-62 49
- 628 Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. **2007**, 30, 1168-72 49
- 627 Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. **2007**, 21, 53-60 54
- 626 Concomitant Occurrence of Non-Alcoholic Fatty Liver Disease and Cholelithiasis. **2007**, 1, 353-360 1
- 625 Bibliography. Current world literature. Genetics and molecular biology. **2007**, 18, 199-221
- 624 Liver-Related Complications in HIV-Infected Individuals. **2007**, 15, 38-48
- 623 Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. **2007**, 17, 684-98 56
- 622 Pioglitazone: the beginning of a new era for NASH?. **2007**, 47, 160-2 13
- 621 Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. **2007**, 47, 142-56 249
- 620 Glucocorticoids, metabolism and metabolic diseases. **2007**, 275, 43-61 334
- 619 Non-alcoholic steatohepatitis in a child with cartilage-hair hypoplasia syndrome. **2007**, 37, 984-987 0
- 618 Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. **2007**, 37, 1034-43 45
- 617 Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica. **2007**, 8, 136-143
- 616 Medical treatment of non-alcoholic steatohepatitis. **2007**, 11, 119-40, ix 26
- 615 A model to estimate insulin sensitivity in dairy cows. **2007**, 49, 29 126
- 614 Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. **2007**, 133, 496-506 397
- 613 Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. **2007**, 13, 3540-53 177

612	Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. <i>Hepatology</i> , <b>2007</b> , 46, 66-73	11.2	112
611	Hepatic steatosis and increased adiposity in mice consuming rapidly vs. slowly absorbed carbohydrate. <b>2007</b> , 15, 2190-9		63
610	Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. <b>2007</b> , 87, 56-65		79
609	Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. <b>2007</b> , 87, 792-806		56
608	Pathology of fatty liver disease. <b>2007</b> , 20 Suppl 1, S40-8		153
607	Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?. <b>2007</b> , 22 Suppl 1, S11-9		30
606	Increased serum gamma-glutamyl-transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C. <b>2007</b> , 22, 1621-6		10
605	Measurement of advanced glycation end products may change NASH management. <b>2007</b> , 22, 1354-5		4
604	Admission risk markers for upper gastrointestinal bleeding: can urgent endoscopy be avoided?. <b>2007</b> , 22, 1355-7		1
603	Prevalence and clinical associations of posttransplant fatty liver disease. <b>2007</b> , 27, 76-80		62
602	Update on non-alcoholic fatty liver disease in children. <b>2007</b> , 26, 409-15		99
601	[Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]. <b>2007</b> , 31, 643-54		3
600	Alcool, syndrome métabolique et obésité impact sur la réponse au traitement. <b>2007</b> , 31, 40-43		2
599	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. <b>2007</b> , 7, 175-80		46
598	Hepatitis C, insulin resistance, and steatosis. <b>2007</b> , 6, 129-137		2
597	Current and novel therapies for the treatment of nonalcoholic steatohepatitis. <b>2007</b> , 1, 343-54		5
596	Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. <b>2008</b> , 18, 1438-42		42
595	A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. <i>Hepatology</i> , <b>2008</b> , 47, 1916-23	11.2	115

594	Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , <b>2008</b> , 48, 28-37	11.2	49
593	Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. <b>2008</b> , 9, 616-22		61
592	Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. <b>2008</b> , 62, 374-81		17
591	ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. <b>2008</b> , 16, 770-6		76
590	Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. <b>2008</b> , 23, 779-82		72
589	The cardiometabolic syndrome and liver disease. <b>2008</b> , 3, 5-6		3
588	Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. <b>2008</b> , 12, 805-24, ix		26
587	Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia. <b>2008</b> , 58, 208-14		7
586	Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. <b>2008</b> , 6, 864-76		52
585	Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. <b>2008</b> , 134, 416-23		399
584	Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. <b>2008</b> , 40, 194-9		209
583	Nonalcoholic fatty liver disease in children. <b>2008</b> , 27, 667-76		54
582	Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. <b>2008</b> , 43, 1128-36		70
581	The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. <b>2008</b> , 82, 983-90		71
580	Oxidative mechanisms in the pathogenesis of alcoholic liver disease. <b>2008</b> , 29, 9-16		211
579	Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis. <b>2008</b> , 18, 545-52		14
578	Evolving trends in nonalcoholic fatty liver disease. <b>2008</b> , 19, 75-82		25
577	Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. <b>2008</b> , 30, 1168-76		97

576	Impact of visceral adipose tissue on liver metabolism and insulin resistance. Part II: Visceral adipose tissue production and liver metabolism. <b>2008</b> , 34, 439-45	48
575	KLF6 in nonalcoholic fatty liver disease: role of fibrogenesis and carcinogenesis. <b>2008</b> , 135, 309-12	6
574	Hepatitis C virus and glucose and lipid metabolism. <b>2008</b> , 34, 692-700	18
573	. <b>2008</b> ,	3
572	Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk?. <b>2008</b> , 8, 301-7	9
571	Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. <b>2008</b> , 28, 1225-36	520
570	Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. <b>2008</b> , 103, 1136-44	149
569	Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. <b>2008</b> , 17, 846-54	80
568	Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice. <b>2008</b> , 198, 309-15	13
567	Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. <b>2008</b> , 2, 705-11	29
566	Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. <b>2008</b> , 115, 1-12	57
565	Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. <b>2008</b> , 26, 2191-7	30
564	Nonalcoholic fatty liver disease: the potential role of nutritional management. <b>2008</b> , 11, 766-73	23
563	The range of normal values of liver enzymes in the era of metabolic syndrome: the need for a redefinition. <b>2008</b> , 20, 589-91	2
562	Non-alcoholic fatty liver disease and the metabolic syndrome: an update. <b>2008</b> , 14, 185-92	237
561	Clinical update on non-alcoholic fatty liver disease and steatohepatitis. <i>Annals of Hepatology</i> , <b>2008</b> , 7, 157-160	3.1 9
560	[Metabolic characteristics and associated factors of nonalcoholic fatty liver disease diagnosed at medical checkups]. <b>2008</b> , 28, 244-50	3
559	Molecular Basis of Liver Disease. <b>2009</b> , 395-419	

558	Fatty Liver Disease. <b>2009</b> , 1087-1114		7
557	Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. <b>2009</b> , 15, 6017-22		58
556	Metabolic syndrome and non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2009</b> , 8, S18-S24	3.1	108
555	Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. <b>2009</b> , 2009, 831670		87
554	Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. <b>2009</b> , 44, 6-14		48
553	Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?. <b>2009</b> , 3, 353-61		4
552	Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents. <b>2009</b> , 32, 695-701		72
551	[Nonalcoholic fatty liver disease: hypotheses and established concepts]. <b>2009</b> , 33, 395-6		0
550	Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. <b>2009</b> , 604, 125-31		29
549	Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2009</b> , 49, 1926-34	11.2	119
548	Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. <b>2009</b> , 115, 5651-61		304
547	Nonalcoholic fatty liver disease during valproate therapy. <b>2009</b> , 168, 1391-4		18
546	Diabetes and apoptosis: liver. <b>2009</b> , 14, 1459-71		30
545	An investigation into disease progression and the correlation between diabetes mellitus and hepatocellular carcinoma. <b>2009</b> , 6, 451-455		
544	Molecular mechanisms involved in NAFLD progression. <b>2009</b> , 87, 679-95		207
543	A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. <b>2009</b> , 379, 241-51		16
542	Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. <b>2009</b> , 30, 947-54		17
541	Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. <b>2009</b> , 29, 213-20		28



540	Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. <b>2009</b> , 29, 1431-8	102
539	Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. <b>2009</b> , 19, 646-53	79
538	Dietary supplementation with chitosan derived from mushrooms changes adipocytokine profile in diet-induced obese mice, a phenomenon linked to its lipid-lowering action. <b>2009</b> , 9, 767-73	67
537	Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future. <b>2009</b> , 50, 648-51	31
536	Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. <b>2009</b> , 41, 586-90	5
535	Non-alcoholic fatty liver disease pathogenesis: the present and the future. <b>2009</b> , 41, 615-25	190
534	Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. <b>2009</b> , 41, 823-8	61
533	Significance of ALT/AST ratio for specifying subjects with metabolic syndrome in its silent stage. <b>2009</b> , 3, 3-6	11
532	Hepatitis C virus and type 2 diabetes. <b>2009</b> , 15, 1537-47	112
531	Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. <b>2009</b> , 13, 591-606	23
530	Pharmacologic therapy of non-alcoholic steatohepatitis. <b>2009</b> , 13, 667-88	24
529	Molecular mechanisms of insulin resistance in chronic hepatitis C. <b>2009</b> , 15, 4356-64	55
528	Matcha, a powdered green tea, ameliorates the progression of renal and hepatic damage in type 2 diabetic OLETF rats. <b>2009</b> , 12, 714-21	25
527	Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. <b>2009</b> , 43, 985-9	56
526	Article Commentary: Insulin Resistance, Type 2 Diabetes and Chronic Liver Disease. A Deadly Trio. <b>2009</b> , 2, CMED.S3518	1
525	Non-Alcoholic Fatty Liver Disease. <b>2009</b> , 1-14	
524	Liver fibrosis and therapeutic strategies: the goal for improving metabolism. <b>2009</b> , 10, 505-12	22
523	On-site Basic Health Screening and Brief Health Counseling of Chronic Medical Conditions for Veterans in Methadone Maintenance Treatment. <b>2010</b> , 4, 160-166	15

522	The importance of fatty liver disease in clinical practice. <b>2010</b> , 69, 518-27		13
521	Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. <b>2010</b> , 22, 18-23		89
520	Metabolic Syndrome and HCV: Where Do We Stand in 2010?. <b>2010</b> , 9, 133-139		0
519	Alcohol drinking may not be a major risk factor for fatty liver in Japanese undergoing a health checkup. <b>2010</b> , 55, 176-82		30
518	Clinical observation paper: fatty liver and metabolic syndrome: is it a burden for the future generations?. <i>Metabolism: Clinical and Experimental</i> , <b>2010</b> , 59, 831-3	12.7	
517	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. <i>Hepatology</i> , <b>2010</b> , 51, 445-53	11.2	260
516	New insights into the role of iron in the development of nonalcoholic fatty liver disease. <i>Hepatology</i> , <b>2010</b> , 52, 408-10	11.2	7
515	Berry meals and risk factors associated with metabolic syndrome. <b>2010</b> , 64, 614-21		39
514	[Patomechanisms of hepatic steatosis]. <b>2010</b> , 151, 323-9		0
513	Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. <b>2010</b> , 3, 43-51		9
512	A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. <b>2010</b> , 51, 500-13		54
511	Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. <b>2010</b> , 59, 1303-7		120
510	AMPK-Dependent Metabolic Regulation by PPAR Agonists. <b>2010</b> , 2010,		65
509	Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis. <b>2010</b> , 28, 783-91		11
508	Leptin: the prototypic adipocytokine and its role in NAFLD. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 1903-12	3.3	46
507	Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. <b>2010</b> , 5, 403-423		16
506	Insulin resistance in nonalcoholic fatty liver disease. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 1941-51	3.3	238
505	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. <b>2010</b> , 42, 272-82		159

504	A position statement on NAFLD/NASH based on the EASL 2009 special conference. <b>2010</b> , 53, 372-84		726
503	Nonalcoholic fatty liver disease: the hepatic trigger of the metabolic syndrome. <b>2010</b> , 53, 1146-7		39
502	NF-kappaB binding activity and pro-inflammatory cytokines expression correlate with body mass index but not glycosylated hemoglobin in Chinese population. <b>2010</b> , 90, 73-80		10
501	The Adaptive Immune System and Liver Toxicity. <b>2010</b> , 275-293		
500	A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. <b>2011</b> , 10, 2797-806		54
499	Type 2 diabetes does not worsen prognosis in hepatocellular carcinoma. <b>2011</b> , 35, 214-20		5
498	ATF4 deficiency protects mice from high-carbohydrate-diet-induced liver steatosis. <i>Biochemical Journal</i> , <b>2011</b> , 438, 283-9	3.8	51
497	IRS2 and PTP1B: Two opposite modulators of hepatic insulin signalling. <b>2011</b> , 117, 105-15		19
496	Current understanding of insulin resistance in hepatitis C. <b>2011</b> , 5, 503-16		33
495	Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. <b>2011</b> , 9, 525-33		26
494	Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. <b>2011</b> , 15, 281-96, vii-x		40
493	Transcriptional co-factors and hepatic energy metabolism. <b>2011</b> , 332, 21-31		12
492	Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. <b>2011</b> , 54, 142-52		72
491	Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. <b>2011</b> , 54, 160-3		57
490	Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones?. <b>2011</b> , 41, 687-95		10
489	Histopathological characteristics of non-alcoholic fatty liver disease in children: Comparison with adult cases. <b>2011</b> , 41, 1066-74		22
488	Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. <i>Annals of Hepatology</i> , <b>2011</b> , 10, 33-37	3.1	34
487	Association Between Fatty Liver and Cardiovascular Disease: Mechanism and Clinical Implications. <b>2011</b> ,		

486	Pathomechanism of insulin resistance in chronic hepatitis C. <b>2011</b> , 5, 284-289	
485	Effect of silybin on high-fat-induced fatty liver in rats. <b>2011</b> , 44, 652-9	29
484	Synergy analysis reveals association between insulin signaling and desmoplakin expression in palmitate treated HepG2 cells. <b>2011</b> , 6, e28138	5
483	Foie m�abolique. <b>2011</b> , 6, 1-12	
482	Does physical inactivity cause nonalcoholic fatty liver disease?. <b>2011</b> , 111, 1828-35	65
481	Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis. <b>2012</b> , 5, 539-44	9
480	Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. <b>2011</b> , 26, 30-46	100
479	Increasing insulin resistance is associated with increased severity and prevalence of gastro-oesophageal reflux disease. <b>2011</b> , 34, 994-1004	33
478	Liver fat in obesity: role of type 2 diabetes mellitus and adipose tissue distribution. <b>2011</b> , 41, 39-44	19
477	Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. <b>2011</b> , 31, 1285-97	281
476	A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. <b>2011</b> , 35, 1361-7	61
475	Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. <b>2011</b> , 35, 270-8	32
474	Nutrient intake in Italian obese patients: relationships with insulin resistance and markers of non-alcoholic fatty liver disease. <b>2011</b> , 27, 672-6	23
473	Hepatitis C virus infection: molecular pathways to insulin resistance. <b>2011</b> , 8, 474	21
472	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. <b>2011</b> , 56, 3439-49	69
471	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <b>2011</b> , 48, 337-343	20
470	Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. <b>2011</b> , 54, 1788-98	73
469	Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease. <b>2011</b> , 26, 202-9	65

468	Variation of serum monocyte chemoattractant protein-1 in patients with diabetes and metabolic syndrome. <b>2011</b> , 31, 312-316	5
467	Intragastric balloon treatment for obesity: results of a large single center prospective study. <b>2011</b> , 21, 551-5	30
466	Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. <b>2011</b> , 22, 699-711	138
465	Impact of insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis. <b>2011</b> , 96, 2398-400	5
464	ASH and NASH. <b>2011</b> , 29, 202-10	59
463	In vitro models for the study of non-alcoholic fatty liver disease. <b>2011</b> , 18, 1079-84	40
462	Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. <b>2011</b> , 60, 1394-402	259
461	Glitazones for human nonalcoholic steatohepatitis. <b>2011</b> , 4, 325-34	8
460	Nonalcoholic Fatty Liver Disease. <b>2011</b> , 435-440	1
459	Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. <b>2011</b> , 29, 243-8	24
458	Human umbilical cord blood-derived mesenchymal stem cells improve glucose homeostasis in rats with liver cirrhosis. <b>2011</b> , 39, 137-43	17
457	Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice. <b>2011</b> , 300, E886-93	66
456	Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. <b>2012</b> , 57, 244-9	35
455	Kupffer Cells. <b>2011</b> , 81-95	4
454	Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. <b>2012</b> , 19, 1889-98	22
453	The impact of bariatric surgery on nonalcoholic steatohepatitis. <b>2012</b> , 32, 80-91	53
452	Peroxisome proliferator-activated receptor $\delta$ agonist attenuates hepatic steatosis by anti-inflammatory mechanism. <b>2012</b> , 44, 578-85	41
451	Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. <b>2012</b> , 107, 561-7	88

450	Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. <b>2012</b> , 92, 1428-39	72
449	Obesity and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. <b>2012</b> , 42, 212-21	38
448	Mitochondrial roles and cytoprotection in chronic liver injury. <b>2012</b> , 2012, 387626	82
447	The pathogenesis of non-alcoholic fatty liver disease is closely related to the metabolic syndrome components. <b>2012</b> , 19, 311-321	1
446	Relationship between several markers and presence of metabolic syndrome or components of the metabolic syndrome in Japanese workers. <b>2012</b> , 54, 984-8	2
445	Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used. <b>2012</b> , 24, 1007-11	24
444	The interaction of metabolic factors with HCV infection: does it matter?. <b>2012</b> , 56 Suppl 1, S56-65	137
443	Perinephric and epididymal fat affect hepatic metabolism in rats. <b>2012</b> , 20, 151-6	11
442	Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. <b>2012</b> , 10, 1162-8; quiz e87	52
441	Hepatic and cardiac steatosis: are they coupled?. <b>2012</b> , 8, 663-70	14
440	[Nonalcoholic fatty liver disease]. <b>2012</b> , 41, 169-89	4
439	Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. <b>2012</b> , 30, 158-62	143
438	Macrophages, TGF- $\beta$ expression and iron deposition in development of NASH. <b>2012</b> , 7, 599-603	1
437	Liver injury in HIV monoinfected patients: should we turn a blind eye to it?. <b>2012</b> , 36, 441-7	7
436	The lipid accumulation product is highly related to serum alanine aminotransferase level in male adults. <b>2012</b> , 32, 581-7	5
435	Frequency of non-alcoholic fatty liver disease in overweight/obese children and adults: Clinical, sonographic picture and biochemical assessment. <b>2012</b> , 10, 221-227	7
434	Oleic acid activates peroxisome proliferator-activated receptor $\alpha$ to compensate insulin resistance in steatotic cells. <b>2012</b> , 23, 1264-70	29
433	Cholesterol and Inflammation at the Crossroads of Non-Alcoholic Fatty Liver Disease (NAFLD) and Atherogenesis. <b>2012</b> ,	1

432	Kinetic studies to investigate lipoprotein metabolism. <b>2012</b> , 271, 166-73	22
431	Nonalcoholic fatty liver disease: the hepatic metabolic syndrome. <b>2012</b> , 24, 345-51	6
430	Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: Evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis. <b>2012</b> , 42, 310-20	10
429	Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. <b>2012</b> , 42, 273-9	9
428	Maternal high-fat feeding through pregnancy and lactation predisposes mouse offspring to molecular insulin resistance and fatty liver. <b>2012</b> , 23, 341-8	137
427	Modulation of cytokines, resistin, and distribution of adipose tissue in C57BL/6 mice by different high-fat diets. <b>2012</b> , 28, 212-9	56
426	Prevalence of hypothyroidism in nonalcoholic fatty liver disease. <b>2012</b> , 57, 528-34	119
425	$\beta$ -Polyunsaturated fatty acids prevent lipoperoxidation, modulate antioxidant enzymes, and reduce lipid content but do not alter glycogen metabolism in the livers of diabetic rats fed on a high fat thermolyzed diet. <b>2012</b> , 361, 151-60	36
424	The role of angiotensin II in nonalcoholic steatohepatitis. <b>2013</b> , 378, 29-40	44
423	Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. <b>2013</b> , 33, 231-48	196
422	Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver. <b>2013</b> , 14, 54	12
421	Intracellular pigment epithelium-derived factor contributes to triglyceride degradation. <b>2013</b> , 45, 2076-86	12
420	Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. <b>2013</b> , 46, 202-8	49
419	Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. <b>2013</b> , 50, 241-9	30
418	Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. <b>2013</b> , 47, 1348-52	21
417	Insulin resistance and early virological response in chronic HCV infection. <b>2013</b> , 11, 69-73	0
416	Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. <b>2013</b> , 45, 162-70	46
415	Hepatic manifestations of metabolic syndrome. <b>2013</b> ,	16

414	Inhibition of CYP2E1 leads to decreased advanced glycated end product formation in high glucose treated ADH and CYP2E1 over-expressing VL-17A cells. <b>2013</b> , 1830, 4407-16	12
413	Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. <b>2013</b> , 27, 489-97	11
412	Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. <b>2013</b> , 30, 545-52	12
411	Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergent-resistant membranes. <i>Hepatology</i> , <b>2013</b> , 57, 525-32	11.2 117
410	Hepatic steatosis development with four weeks of physical inactivity in previously active, hyperphagic OLETF rats. <b>2013</b> , 304, R763-71	17
409	Predictive value of the adiponectin to leptin ratio for diagnosis of steatohepatitis in patients with nonalcoholic fatty liver disease. <b>2013</b> , 3, 47-53	
408	Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. <b>2013</b> , 218, R25-36	180
407	Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. <b>2013</b> , 62, 324-30	71
406	Plasma levels of adiponectin and primary liver cancer risk in middle-aged Japanese adults with hepatitis virus infection: a nested case-control study. <b>2013</b> , 22, 2250-7	12
405	Body fat distribution and risk factors for fibrosis in patients with alcoholic liver disease. <b>2013</b> , 37, 332-8	22
404	Metabolic factors and chronic hepatitis C: a complex interplay. <b>2013</b> , 2013, 564645	23
403	Ilexgenin A Obtained from <i>Ilex hainanensis</i> Merr. Improves Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats. <b>2013</b> , 74, 227-236	7
402	Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. <b>2013</b> , 52 Suppl 1, E139-47	49
401	Non-alcoholic fatty liver disease is associated with benign prostate hyperplasia in men and with overactive bladder in women. <b>2013</b> , 47, 497-502	6
400	Cardiorespiratory fitness, but not central obesity or C-reactive protein, is related to liver function in obese children. <b>2013</b> , 25, 3-11	7
399	Anti-inflammatory effects of total alkaloids from <i>Rubus alceifolius</i> Poir [corrected]. on non-alcoholic fatty liver disease through regulation of the NF- $\kappa$ B pathway. <b>2013</b> , 31, 931-7	11
398	Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. <b>2013</b> , 2013, 493413	49
397	Epidemiology and natural history of patients with NAFLD. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 5169-76	106



396	Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study. <b>2014</b> , 9, e96651		17
395	Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: a pilot study. <b>2014</b> , 2014, 169216		55
394	The metabolic syndrome and chronic liver disease. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 5010-24	3.3	27
393	Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. <b>2014</b> , 5, 586-600		66
392	New mechanisms contributing to hepatic steatosis: glucose, insulin, and lipid signaling. <b>2014</b> , 18, 77-82		6
391	A vascular piece in the puzzle of adipose tissue dysfunction: mechanisms and consequences. <b>2014</b> , 120, 1-11		8
390	Insulin resistance provides the connection between hepatitis C virus and diabetes. <b>2015</b> , 15, e23941		9
389	Inhibition of peroxisome proliferator-activated receptor $\alpha$ potential link between chronic maternal hypoxia and impaired fetal growth. <b>2014</b> , 28, 1268-79		9
388	Alanine aminotransferase elevation in obese infants and children: a marker of early onset non alcoholic Fatty liver disease. <b>2014</b> , 14, e14112		12
387	Hypoadiponectinaemia in nonalcoholic fatty liver disease obese women is associated with infrequent intake of dietary sucrose and fatty foods. <b>2014</b> , 27 Suppl 2, 301-12		5
386	Hepatitis C virus NS5A protein enhances gluconeogenesis through upregulation of Akt-/JNK-PEPCK signalling pathways. <b>2014</b> , 34, 1358-68		10
385	Prevalence of and factors influencing impaired glucose tolerance among hepatitis B carriers: a nationwide cross-sectional study in the Republic of Korea. <b>2014</b> , 93, e91		2
384	Liver function breath tests for differentiation of steatohepatitis from simple fatty liver in patients with nonalcoholic Fatty liver disease. <b>2014</b> , 48, 59-65		6
383	Lipid Metabolism in Metabolic Syndrome. <b>2014</b> , 157-170		
382	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. <b>2014</b> , 60, 1055-62		57
381	Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone. <b>2014</b> , 13, 7		8
380	Microbiota and nonalcoholic steatohepatitis. <b>2014</b> , 36, 115-32		29
379	CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). <b>2014</b> , 36, 55-71		31

378	Hydrogen sulfide and the liver. <b>2014</b> , 41, 62-71		108
377	Energy metabolism and fertility: a balance preserved for female health. <b>2014</b> , 10, 13-23		70
376	A Systems Biology Approach to Study Metabolic Syndrome. <b>2014</b> ,		1
375	Evaluation of clinical and inflammatory markers of nonalcoholic fatty liver disease in postmenopausal women with metabolic syndrome. <b>2014</b> , 12, 330-8		6
374	Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 1542-52	12.7	75
373	Activation of hepatic inflammatory pathways by catecholamines is associated with hepatic insulin resistance in male ischemic stroke rats. <b>2014</b> , 155, 1235-46		34
372	Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women. <b>2014</b> , 17, 465-71		14
371	Extracts from <i>Salvia-Nelumbinis naturalis</i> alleviate hepatosteatosis via improving hepatic insulin sensitivity. <b>2014</b> , 12, 236		20
370	The impact of obesity and metabolic syndrome on chronic hepatitis C. <b>2014</b> , 18, 147-56		20
369	Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. <i>FEBS Journal</i> , <b>2014</b> , 281, 2503-24	5.7	46
368	A model integration approach linking signalling and gene-regulatory logic with kinetic metabolic models. <b>2014</b> , 124, 26-38		14
367	The impact of obesity on liver histology. <b>2014</b> , 18, 33-40		21
366	Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). <b>2014</b> , 31, 30-43		35
365	Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. <b>2014</b> , 20, 18070-91		208
364	Connection Between Non-Alcoholic Fatty Liver Disease and Diabetes Mellitus. <b>2014</b> , 21, 121-127		2
363	Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. <b>2015</b> , 15, 169		47
362	Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. <b>2015</b> , 23, 965-72		26
361	The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. <b>2015</b> , 38, 694-702		44

360	Nonalcoholic fatty liver disease. <b>2015</b> , 1, 15080		366
359	Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice. <b>2015</b> , 12, 6895-902		13
358	Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. <b>2015</b> , 16, 871-82		15
357	Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. <b>2015</b> , 14, 67		27
356	Inhibition of IRS-1 by hepatitis C virus infection leads to insulin resistance in a PTEN-dependent manner. <b>2015</b> , 12, 12		19
355	Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <b>2015</b> , 94, e1103		6
354	Insulin resistance and its consequences in chronic hepatitis C. <b>2015</b> , 1, 17-29		9
353	Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. <b>2015</b> , 7, 559-65		29
352	Hepatic circadian-clock system altered by insulin resistance, diabetes and insulin sensitizer in mice. <b>2015</b> , 10, e0120380		15
351	Irisin and Myonectin Regulation in the Insulin Resistant Muscle: Implications to Adipose Tissue: Muscle Crosstalk. <i>Journal of Diabetes Research</i> , <b>2015</b> , 2015, 359159	3.9	64
350	Taraxacum officinale and Silybum marianum alone or combined orchestrate experimentally induced hepatic steatosis through lipogenicity, glucose tolerance and oxidant/antioxidant status. <b>2015</b> , 9, 1918		1
349	Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. <b>2015</b> , 5, 51-68		78
348	Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. <b>2015</b> , 33, 426-32		10
347	Gut microbiota and non-alcoholic fatty liver disease. <b>2015</b> , 14, 572-81		45
346	Animal Models Correlating Immune Cells for the Development of NAFLD/NASH. <b>2015</b> , 5, 239-45		12
345	Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats. <b>2015</b> , 11, 603-10		27
344	Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. <b>2015</b> , 3, 141-5		41
343	Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. <b>2015</b> , 33, 743-51		19

342	Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH. <b>2015</b> , 29, 1564-76	51
341	Genetic architecture of insulin resistance in the mouse. <b>2015</b> , 21, 334-347	126
340	Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?. <b>2015</b> , 418 Pt 1, 55-65	177
339	Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. <b>2015</b> , 41, 1948-57	24
338	Dual effect of red wine on liver redox status: a concise and mechanistic review. <b>2015</b> , 89, 1681-93	8
337	Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. <b>2015</b> , 7, 121-7	46
336	Metformin protects primary rat hepatocytes against oxidative stress-induced apoptosis. <b>2015</b> , 3, e00125	29
335	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. <b>2015</b> , 35, 236-49	54
334	Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats. <b>2015</b> , 8, 1213-25	12
333	Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis. <b>2015</b> , 227, 179-91	21
332	Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases. <b>2015</b> , 337, 10-20	26
331	Pathophysiological basis for compromised health beyond generations: role of maternal high-fat diet and low-grade chronic inflammation. <b>2015</b> , 26, 1-8	37
330	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. <b>2015</b> , 47, 181-90	430
329	Insights and challenges in using <i>C. elegans</i> for investigation of fat metabolism. <b>2015</b> , 50, 69-84	28
328	Sirtuins and nonalcoholic fatty liver disease. <b>2016</b> , 22, 10084-10092	74
327	Metabolic aspects of adult patients with nonalcoholic fatty liver disease. <b>2016</b> , 22, 7006-16	107
326	Effect of Alkaloids from <i>Nelumbinis Plumula</i> against Insulin Resistance of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. <i>Journal of Diabetes Research</i> , <b>2016</b> , 2016, 3965864	3.9 7
325	Acute Fatty Liver of Pregnancy: A Life-Threatening Condition Requiring a Life-Saving Approach. <b>2016</b> , 16, e35256	2

324	Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation. <b>2016</b> , 16, e132-41		168
323	Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	111
322	Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease. <b>2016</b> , 23, 260-9		10
321	Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers. <b>2016</b> , 238, 531-42		25
320	Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome. <b>2016</b> , 6, 117-23		10
319	Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. <b>2016</b> , 54, 2995-3000		19
318	Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development. <b>2016</b> , 11, 723-738		29
317	Long-Term Single and Joint Effects of Excessive Daytime Napping on the HOMA-IR Index and Glycosylated Hemoglobin: A Prospective Cohort Study. <b>2016</b> , 95, e2734		8
316	Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. <i>Scientific Reports</i> , <b>2016</b> , 6, 38605	4.9	20
315	CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. <i>Scientific Reports</i> , <b>2016</b> , 6, 28786	4.9	68
314	Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. <b>2016</b> , 51, 1141-1149		29
313	Flaxseed lignans alleviate high fat diet-induced hepatic steatosis and insulin resistance in mice: Potential involvement of AMP-activated protein kinase. <b>2016</b> , 24, 482-491		17
312	Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <b>2016</b> , 61, 2389-2396		29
311	Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk. <b>2016</b> , 26, 623-629		18
310	Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. <b>2016</b> , 15, 133		15
309	Nrf2 in Type 2 diabetes and diabetic complications: Yin and Yang. <b>2016</b> , 1, 9-19		12
308	Histological Biomarkers of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 1-13		
307	M1-/M2-macrophage polarization in pseudolobules consisting of adipophilin-rich hepatocytes in thioacetamide (TAA)-induced rat hepatic cirrhosis. <b>2016</b> , 101, 133-42		10

306	Positive hepatitis B surface antibody is associated with reduced risk of diabetes mellitus in retired female Chinese workers. <b>2016</b> , 8, 158-61	6
305	Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. <b>2016</b> , 34 Suppl 1, 3-10	19
304	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <b>2016</b> , 15, 1145-1160	69
303	Treatment of nonalcoholic fatty liver disease: role of AMPK. <b>2016</b> , 311, E730-E740	243
302	Hepatogener Diabetes. <b>2016</b> , 12, 468-472	0
301	Inhibitory effects of extracts on palmitate-induced lipotoxicity in HepG2 cells. <b>2016</b> , 25, 1709-1717	4
300	Deletion of Nrf2 leads to hepatic insulin resistance via the activation of NF- $\kappa$ B in mice fed a high-fat diet. <b>2016</b> , 14, 1323-31	26
299	Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. <b>2016</b> , 95, e4947	34
298	The Liver in Systemic Diseases. <b>2016</b> ,	1
297	Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet. <b>2016</b> , 591, 57-65	59
296	Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. <b>2016</b> , 21, 11-23	122
295	Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflamm. <b>2016</b> , 61, 1325-36	124
294	The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. <b>2016</b> , 10, 289-98	29
293	Diet-induced dyslipidemia leads to nonalcoholic fatty liver disease and oxidative stress in guinea pigs. <b>2016</b> , 168, 146-160	28
292	Is There Any Relation Between the Degree of Fatty Liver Disease and Severity of Lower Urinary Tract Symptoms?. <b>2016</b> , 89, 90-5	4
291	Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. <b>2016</b> , 113, 179-86	5
290	A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/nitrate in rats. <b>2016</b> , 54, 51-9	23
289	Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. <b>2016</b> , 64, 925-32	109

288	Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. <b>2016</b> , 20, 375-87		16
287	Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. <b>2016</b> , 12, 127-31		53
286	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <b>2017</b> , 49, 471-483		179
285	Impact of hepatitis C virus therapy on metabolism and public health. <b>2017</b> , 37 Suppl 1, 13-18		19
284	Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice. <b>2017</b> , 69, 698-705		10
283	Isoflurane anesthesia induces liver injury by regulating the expression of insulin-like growth factor 1. <b>2017</b> , 13, 1608-1613		10
282	High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 72, 37-46	12.7	24
281	The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury. <b>2017</b> , 95, 443-453		19
280	Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. <b>2017</b> , 38, 649-665		172
279	Promising effect of extract on high-fat diet-induced nonalcoholic fatty liver. <b>2017</b> , 7, 508-514		20
278	Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. <b>2017</b> , 35, 282-287		20
277	Lipid overload during gestation and lactation can independently alter lipid homeostasis in offspring and promote metabolic impairment after new challenge to high-fat diet. <b>2017</b> , 14, 16		32
276	Potential hypoglycaemic activity phenolic glycosides from <i>Moringa oleifera</i> seeds. <b>2017</b> , 31, 1869-1874		24
275	Insulin resistance in Alzheimer's disease. <b>2017</b> , 183, 26-40		64
274	Association between HOMA-IR and Lung Function in Korean Young Adults based on the Korea National Health and Nutrition Examination Survey. <i>Scientific Reports</i> , <b>2017</b> , 7, 11726	4.9	8
273	CTRP1 in Liver Disease. <b>2017</b> , 79, 1-23		13
272	Early menarche is associated with non-alcoholic fatty liver disease in adulthood. <b>2017</b> , 59, 1270-1275		13
271	Function and Dysfunction of Adipose Tissue. <b>2017</b> , 19, 3-31		18

270	Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. <b>2017</b> , 10, 701-713	26
269	Previous physical exercise alters the hepatic profile of oxidative-inflammatory status and limits the secondary brain damage induced by severe traumatic brain injury in rats. <b>2017</b> , 595, 6023-6044	22
268	High fat diet induces brain insulin resistance and cognitive impairment in mice. <b>2017</b> , 1863, 499-508	128
267	n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis. <i>Nutrients</i> , <b>2017</b> , 9, 6.7	42
266	Nonalcoholic fatty liver disease: Evolving paradigms. <b>2017</b> , 23, 6571-6592	92
265	Antiangiogenic Therapy for Hepatocellular Carcinoma. <b>2017</b> ,	
264	Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. <b>2017</b> , 135, 277-295	19
263	Negative legacy of obesity. <b>2017</b> , 12, e0186303	21
262	Conversion of Sugar to Fat: Is Hepatic de Novo Lipogenesis Leading to Metabolic Syndrome and Associated Chronic Diseases?. <b>2017</b> , 117, 520-527	13
261	MiR-19a mediates gluconeogenesis by targeting PTEN in hepatocytes. <b>2018</b> , 17, 3967-3971	9
260	Acetone fraction from <i>Sechium edule</i> (Jacq.) S.w. edible roots exhibits anti-endothelial dysfunction activity. <b>2018</b> , 220, 75-86	4
259	Chronic liver diseases and the potential use of S-adenosyl-L-methionine as a hepatoprotector. <b>2018</b> , 30, 893-900	14
258	Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. <b>2018</b> , 190, 81-90	30
257	Aspalathin from Rooibos ( <i>Aspalathus linearis</i> ): A Bioactive C-glucosyl Dihydrochalcone with Potential to Target the Metabolic Syndrome. <b>2018</b> , 84, 568-583	40
256	Is non-alcoholic fatty liver disease a reflection of what we eat or simply how much we eat?. <b>2018</b> , 2, 59-74	8
255	Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes. <b>2018</b> , 65, 354-360	7
254	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. <b>2018</b> , 64, 135-146	61
253	Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials. <b>2018</b> , 37, 113-122	35



252	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. <b>2018</b> , 37, 37-55	66
251	The association of non-alcoholic fatty liver disease with lung function: A survey design analysis using propensity score. <b>2018</b> , 23, 82-88	12
250	Does iris(in) bring bad news or good news?. <b>2018</b> , 23, 431-442	11
249	In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections. <b>2018</b> , 25, 262-271	2
248	Ultrasound Entropy Imaging of Nonalcoholic Fatty Liver Disease: Association with Metabolic Syndrome. <b>2018</b> , 20,	15
247	Blood Sugar Control and Low-Carbohydrate High-Fat Diet. <b>2018</b> , 19, 237	
246	miR-338-3p mediates gluconeogenesis via targeting of PP4R1 in hepatocytes. <b>2018</b> , 18, 4129-4137	4
245	Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. <b>2018</b> , 46, 4447-4454	7
244	Differential impacts of mineralocorticoid receptor antagonist potassium canrenoate on liver and renal changes in high fat diet-mediated early hepatocarcinogenesis model rats. <b>2018</b> , 43, 611-621	2
243	GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice. <b>2018</b> , 159, 3340-3350	8
242	Hydrogen Therapy in Cardiovascular and Metabolic Diseases: from Bench to Bedside. <b>2018</b> , 47, 1-10	26
241	Mechanisms of NAFLD development and therapeutic strategies. <b>2018</b> , 24, 908-922	1110
240	Diabetes Mellitus and Liver Surgery: The Effect of Diabetes on Oxidative Stress and Inflammation. <b>2018</b> , 2018, 2456579	23
239	Plasma lecithin:cholesterol acyltransferase and phospholipid transfer protein activity independently associate with nonalcoholic fatty liver disease. <b>2018</b> , 48, e12988	11
238	Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease. <b>2018</b> , 277, 21-27	16
237	The Adaptive Immune System and Liver Toxicity. <b>2018</b> , 346-367	1
236	Dietary Fibers: A Way to a Healthy Microbiome. <b>2018</b> , 299-345	9
235	Catalase and nonalcoholic fatty liver disease. <b>2018</b> , 470, 1721-1737	26

234	Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes. <b>2018</b> , 65, 354-360		
233	Suppression of NF- $\kappa$ B activation by PDLIM2 restrains hepatic lipogenesis and inflammation in high fat diet induced mice. <b>2018</b> , 503, 564-571		9
232	Time-restricted feeding suppresses excess sucrose-induced plasma and liver lipid accumulation in rats. <b>2018</b> , 13, e0201261		11
231	Long-term effects of increased protein intake after weight loss on intrahepatic lipid content and implications for insulin sensitivity: a PREVIEW study. <b>2018</b> , 315, E885-E891		14
230	Alpha-Mangostin Improves Insulin Secretion and Protects INS-1 Cells from Streptozotocin-Induced Damage. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	18
229	Probing insulin sensitivity in diabetic kidney disease: is there a stronger role for functional imaging?. <b>2018</b> , 132, 1085-1095		3
228	Plasma ApoE elevations are associated with NAFLD: The PREVENT Study. <b>2019</b> , 14, e0220659		6
227	Dietary Glycotoxins Impair Hepatic Lipidemic Profile in Diet-Induced Obese Rats Causing Hepatic Oxidative Stress and Insulin Resistance. <b>2019</b> , 2019, 6362910		6
226	Natural course of fatty liver in 36,195 South Korean adults. <i>Scientific Reports</i> , <b>2019</b> , 9, 9062	4.9	2
225	Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study. <b>2019</b> , 6, e000295		19
224	Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	6
223	Inhibition of Mitochondrial Fatty Acid Oxidation Contributes to Development of Nonalcoholic Fatty Liver Disease Induced by Environmental Cadmium Exposure. <b>2019</b> , 53, 13992-14000		33
222	Transcriptional Regulation of Early Growth Response Gene-1 (EGR1) is Associated with Progression of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Insulin Resistance. <b>2019</b> , 25, 2293-3004		5
221	Lipid mediators of insulin signaling in diabetic kidney disease. <b>2019</b> , 317, F1241-F1252		13
220	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <b>2019</b> , 8,		6
219	The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice. <b>2019</b> , 416, 1-14		22
218	Drug repurposing in alternative medicine: herbal digestive Sochehwan exerts multifaceted effects against metabolic syndrome. <i>Scientific Reports</i> , <b>2019</b> , 9, 9055	4.9	6
217	Adenovirus-mediated expression of SIK1 improves hepatic glucose and lipid metabolism in type 2 diabetes mellitus rats. <b>2019</b> , 14, e0210930		7

216	Insulin resistance and plasma glucose tolerance abnormalities in Nigerians with chronic liver disease. <b>2019</b> , 13, 2208-2213		
215	SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. <b>2019</b> , 12, 291-306		3
214	Advances in the role of HCV nonstructural protein 5a (NS5A) of 3a genotype in inducing insulin resistance by possible phosphorylation of AKT/PKB. <i>Scientific Reports</i> , <b>2019</b> , 9, 6150	4.9	3
213	Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	88
212	Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. <b>2019</b> , 13, 505-514		6
211	MiR-15b can target insulin receptor to regulate hepatic insulin signaling in mice. <b>2019</b> , 23, 82-89		3
210	Interesterified Fats Induce Deleterious Effects on Adipose Tissue and Liver in LDLr-KO Mice. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	6
209	Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. <b>2019</b> , 39, 1217-1225		5
208	Hepatic miR-215 target Rictor and modulation of hepatic insulin signalling in rats. <b>2019</b> , 19, 3723-3731		4
207	Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	31
206	Hepatoprotective Potential of against STZ-Induced Diabetic Liver Damage in Wistar Rats by Inhibiting Cytokines and the Apoptosis Pathway. <b>2019</b> , 2019, 7958701		11
205	Dyslipidaemia is common among patients with type 2 diabetes: a cross-sectional study at Tema Port Clinic. <b>2019</b> , 12, 204		2
204	Dietary Manipulations for Nonalcoholic Fatty Liver Disease (NAFLD). <b>2019</b> , 69-88		2
203	SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. <b>2019</b> , 7, e14286		7
202	Hepatoprotective Effects of a Ruthenium(II) Schiff Base Complex in Rats with Diet-Induced Prediabetes. <b>2019</b> , 91, 66-72		2
201	Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. <b>2019</b> , 31, 859-864		8
200	The Liver Fat Fraction and Abdominal Subcutaneous and Visceral Fat Volume Distribution in Normal-Weight, Overweight, and Obese Children Using a New Magnetic Resonance Imaging Technique. <b>2019</b> , 43, 194-199		5
199	The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. <b>2019</b> , 31, 703-715		9

198	Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	6
197	Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. <b>2019</b> , 111, 68-75		18
196	Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases. <b>2019</b> , 109, 2237-2251		81
195	Fructose threshold for inducing organ damage in a rat model of nonalcoholic fatty liver disease. <b>2019</b> , 62, 101-112		6
194	Arsenic Contamination in Asia. <b>2019</b> ,		2
193	Arsenic Exposure and Lifestyle-Related Diseases. <b>2019</b> , 83-118		1
192	Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?. <b>2019</b> , 20, 353-363		22
191	Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease. <b>2019</b> , 9, 607-618		23
190	Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol. <b>2019</b> , 60, 168-175		12
189	Alterations in lipid peroxidation, lipid profile, insulin sensitivity, and hepatic histopathological changes in diabetic rats following the treatment with <i>Salvadora persica</i> . <b>2019</b> , 120, 3696-3708		4
188	Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice. <i>Hepatology</i> , <b>2020</b> , 71, 1609-1625	11.2	15
187	Evaluation of probiotics for improving and regulation metabolism relevant to type 2 diabetes in vitro. <b>2020</b> , 64, 103664		5
186	Emulsions loaded with dihydromyricetin enhance its transport through Caco-2 monolayer and improve anti-diabetic effect in insulin resistant HepG2 cell. <b>2020</b> , 64, 103672		22
185	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. <b>2020</b> , 49, 141-149		9
184	Lycopene induces insulin signaling and alleviates fibrosis in experimental model of non-alcoholic fatty liver disease in rats. <b>2020</b> , 14, 100225		2
183	The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. <b>2020</b> , 64, e2000375		17
182	Bioprospecting Cultivated Tropical Green Algae, ( <i>Forsskal</i> ) <i>J. Agardh</i> : A Perspective on Nutritional Properties, Antioxidative Capacity and Anti-Diabetic Potential. <b>2020</b> , 9,		14
181	Plasma metabolomic study in perinatally HIV-infected children using 1H NMR spectroscopy reveals perturbed metabolites that sustain during therapy. <b>2020</b> , 15, e0238316		3

180	The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods. <b>2020</b> , 2020, 5023157		7
179	Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. <b>2020</b> , 73, 800-806		19
178	The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. <b>2020</b> , 36, 198-205		5
177	Ginsenoside Rg2 Ameliorates High-Fat Diet-Induced Metabolic Disease through SIRT1. <b>2020</b> , 68, 4215-4226		15
176	Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications. <b>2020</b> , 69, 517-524		25
175	Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. <b>2020</b> , 20, 210		9
174	Host microbiota dictates the proinflammatory impact of LPS in the murine liver. <b>2020</b> , 67, 104920		7
173	Leptin as a Key Player in Insulin Resistance of Liver Cirrhosis? A Cross-Sectional Study in Liver Transplant Candidates. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
172	Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. <b>2020</b> , 45, 147-161		3
171	Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. <b>2020</b> , 5, 295-305		44
170	Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4. <b>2020</b> , 9, 57-67		10
169	Insulin resistance and the role of gamma-aminobutyric acid. <b>2021</b> , 26, 39		1
168	Oleic Acid and Eicosapentaenoic Acid Reverse Palmitic Acid-induced Insulin Resistance in Human HepG2 Cells via the Reactive Oxygen Species / JUN Pathway. <b>2021</b> ,		2
167	Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. <b>2021</b> , 39, 961-969		0
166	Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis. <b>2021</b> , 19,		13
165	Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance. <b>2021</b> , 53, e14060		0
164	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. <b>2021</b> , 11,		12
163	Assessment of the relationship of serum liver enzymes activity with general and abdominal obesity in an urban Bangladeshi population. <i>Scientific Reports</i> , <b>2021</b> , 11, 6640	4.9	9

162	Dietary vitamin D equilibrium in serum ameliorates direct bilirubin associated diabetes mellitus. <b>2021</b> , 337, 109399		1
161	Anti-hyperglycemic effects of dihydromyricetin in streptozotocin-induced diabetic rats. <b>2021</b> , 10, 155-162		5
160	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	2
159	Nonalcoholic fatty liver and left ventricular remodelling: now the prospective evidence. <b>2021</b> , 39, 864-866		0
158	Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach. <b>2021</b> , 385, 497-518		2
157	Gamma-aminobutyric acid attenuates insulin resistance in type 2 diabetic patients and reduces the risk of insulin resistance in their offspring. <b>2021</b> , 138, 111440		6
156	Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	6
155	Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. <b>2021</b> , 1-23		3
154	Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis. <b>2021</b> , 13, 815-829		0
153	Ameliorates Non-Alcoholic Fatty Liver Disease by Inhibiting Oxidative Stress-Mediated Steatosis and Apoptosis through NRF2-ARE Activation. <b>2021</b> , 10,		4
152	Prediction of Cardiovascular Risk Using Nonalcoholic Fatty Liver Disease Scoring Systems. <b>2021</b> , 9,		0
151	Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus. <b>2021</b> , 15, 708547		3
150	Hepatoprotection of capsaicin in alcoholic and non-alcoholic fatty liver diseases. <b>2021</b> , 1-11		2
149	Sea grapes' extract improves blood glucose, total cholesterol, and PGC-1 $\beta$ in rats fed on cholesterol- and fat-enriched diet.. <b>2021</b> , 10, 718		3
148	CORRELATION BETWEEN HCV RNA VIRAL LOAD AND HOMA-IR IN CHRONIC HEPATITIS C PATIENTS. <b>2021</b> , 2, 29		
147	Gut-flora metabolites is not associated with synchronous carotid artery plaque and non-alcoholic fatty liver disease in asymptomatic adults: A STROBE-compliant article. <b>2021</b> , 100, e27048		0
146	Identification of 90 NAFLD GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease.. <b>2022</b> , 3, 100056		0
145	Saskatoon berry powder reduces hepatic steatosis and insulin resistance in high fat-high sucrose diet-induced obese mice. <b>2021</b> , 95, 108778		2

144	Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. <b>2021</b> , 1		1
143	4,4'-Dichloro-diphenyl diselenide modulated oxidative stress that differently affected peripheral tissues in streptozotocin-exposed mice. <b>2021</b> , 99, 943-951		1
142	Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Peripheral Diabetic Polyneuropathy: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	0
141	Predictive Modeling of MAFLD Based on Hsp90 $\alpha$ and the Therapeutic Application of Teprenone in a Diet-Induced Mouse Model. <b>2021</b> , 12, 743202		0
140	Sea grapes' extract improves blood glucose, total cholesterol, and PGC-1 $\beta$ in rats fed on cholesterol- and fat-enriched diet. 10, 718		0
139	Reducing hepatic endoplasmic reticulum stress ameliorates the impairment in insulin signaling induced by high levels of $\beta$ -hydroxybutyrate in bovine hepatocytes. <b>2021</b> , 104, 12845-12858		1
138	Ameliorative Effect of (Graviola) Extract on Hyperglycemia Induced Hepatic Damage in Type 2 Diabetic Mice. <b>2021</b> , 10,		2
137	Obesity and Non-Alcoholic Fatty Liver Disease: Pathophysiology and Management Focused. <b>2021</b> , 3, 6-12		
136	Potential protective effect of curcumin in high-fat diet-induced nonalcoholic fatty liver disease in rats. <b>2021</b> , 6, 92		2
135	Histological Biomarkers of Nonalcoholic Fatty Liver Disease. <b>2017</b> , 693-705		1
134	Isohumulones from Beer Modulate Blood Lipid Status. <b>2009</b> , 815-829		1
133	Short-Chain Fatty Acid Production and Functional Aspects on Host Metabolism. <b>2018</b> , 37-106		12
132	The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study. <b>2020</b> , 44, 375-383		4
131	Adipose tissue-liver crosstalk during pathologic changes caused by vinyl chloride metabolites in mice. <b>2020</b> , 399, 115068		3
130	Peroxisome proliferator-activated receptor gamma blunts endothelin-1-mediated contraction of the uterine artery in a murine model of high-altitude pregnancy. <b>2020</b> , 34, 4283-4292		2
129	Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. <b>2016</b> , 126, 4361-4371		131
128	Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. <b>2012</b> , 7, e43736		22
127	Changes in the daily rhythm of lipid metabolism in the diabetic retina. <b>2014</b> , 9, e95028		19

126	A Unifying Organ Model of Pancreatic Insulin Secretion. <b>2015</b> , 10, e0142344		9
125	Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. <b>2016</b> , 11, e0162368		57
124	The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis. <b>2017</b> , 12, e0169740		29
123	The Prevalence of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus in an Iranian Population. <b>2017</b> , 9, 86-93		3
122	Comorbidities and Metabolic Derangement of NAFLD. <b>2015</b> , 5, 7-13		40
121	The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. <b>2020</b> , 112, 627-635		6
120	Genetic factors associated with risk of metabolic syndrome and hepatocellular carcinoma. <b>2017</b> , 8, 35403-354116		
119	Effects of Pterostilbene on Diabetes, Liver Steatosis and Serum Lipids. <b>2021</b> , 28, 238-252		14
118	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , <b>2019</b> , 110, 401-409	2.2	9
117	Significance of Serum Adiponectin and Insulin Resistance Levels in Diagnosis of Egyptian Patients with Chronic Liver Disease and HCC. <b>2019</b> , 20, 1833-1839		4
116	Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia. <b>2020</b> , 35, e164		2
115	[The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease]. <b>2009</b> , 15, 59-69		10
114	[Pathology of nonalcoholic steatohepatitis]. <b>2009</b> , 15, 122-30		3
113	Association of serum alanine aminotransferase and $\gamma$ -glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. <b>2011</b> , 17, 27-36		45
112	Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. <b>2020</b> , 12,		8
111	Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. <b>2008</b> , 14, 2474-86		135
110	Hepatic steatosis: a benign disease or a silent killer. <b>2008</b> , 14, 4120-6		49
109	Blood F2-isoprostanes are significantly associated with abnormalities of lipid status in rats with steatosis. <b>2008</b> , 14, 4677-83		10



108	Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. <b>2010</b> , 16, 2265-71	84
107	Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings. <b>2010</b> , 16, 4169-75	11
106	Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology. <b>2010</b> , 16, 5280-5	34
105	IB kinase-beta inhibitor attenuates hepatic fibrosis in mice. <b>2011</b> , 17, 5203-13	12
104	Resistin mediates the hepatic stellate cell phenotype. <b>2013</b> , 19, 4475-85	21
103	Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. <b>2014</b> , 20, 569-77	58
102	Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C. <b>2014</b> , 20, 10449-56	7
101	Osthon attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistance. <b>2014</b> , 20, 11753-61	11
100	MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease. <b>2014</b> , 20, 17914-23	38
99	Changes in human hepatic metabolism in steatosis and cirrhosis. <b>2017</b> , 23, 2685-2695	21
98	Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. <b>2017</b> , 21, 341-354	29
97	Insulin resistance with impaired fasting glucose increases the risk of NAFLD. <b>2013</b> , 03, 170-176	4
96	Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Disease (CAD) in Patients with Angina Pectoris. <b>2013</b> , 03, 97-101	4
95	Lipoic Acid prevents the changes of intracellular lipid partitioning by free Fatty Acid. <b>2013</b> , 7, 221-7	3
94	The Effect of Alpha-Lipoic Acid on Liver Function and Metabolic Markers in Obese Patients with Non-Alcoholic Fatty Liver Disease: A Double - Blind Randomized Controlled Trial. <b>2018</b> , 20,	2
93	Targeting adipose tissue to tackle NASH: SPARCL1 as an emerging player. <b>2021</b> , 131,	1
92	State-of-the-Art Lecture: Non-alcoholic steatohepatitis: concepts on pathogenesis and therapy. <b>2009</b> , 120-124	
91	Serum leptin, adiponectin and resistin levels in obese children and their correlations with insulin resistance. <b>2009</b> , 52, 766	3

- 90 Carbohydrate-deficient transferrin, a sensitive biomarker and diagnostic parameter in non-alcoholic fatty liver. **2009**, 3, 479-486
- 89 Hepatitis C Virus and Insulin Signaling. **2010**, 483-491
- 88 Hepatic Carbohydrate Metabolism. **2011**, 109-123
- 87 Fatty Liver. **2011**, 437-447
- 86 Relationship between Bone Morphological Microstructure and Inflammatory Markers in Growing Mice Fed a High Fat Diet. **2011**, 44, 481 2
- 85 Alcohol in Non-Alcoholic Fatty Liver Disease: an Oxymoron or a New Standard of Care?. 234-247
- 84 Diabetes and NAFLD: Why is the Connection Important?. 62-70
- 83 Nonalcoholic Fatty Liver Disease. **2014**, 345-359
- 82 Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?. **2014**, 20, 151-3
- 81 Fatty Liver Vulnerability to Hypoxic and Inflammatory Stress. **2014**, 27-52
- 80 The Antioxidant, Anti-inflammatory, and Antiapoptotic Effects of Wolfberry in Fatty Liver Disease. **2015**, 45-63
- 79 Physical training at sub-threshold intensity reduces the prevalence of hepatic steatosis after high-fat diet in rats. **2015**, 21, 8-14
- 78 Metabolic Syndrome and the Liver. **2016**, 149-177
- 77 SONOGRAPHICALLY DIAGNOSED NON-ALCOHOLIC FATTY LIVER AS A PREDICTOR OF METABOLIC SYNDROME. **2016**, 5,
- 76 Biomarkers in Focus: Alanine Aminotransferase. **2017**, 267-280 1
- 75 The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. **2020**, 54, 411-415 1
- 74 Adenovirus-mediated expression of SIK1 improves hepatic glucose and lipid metabolism in type 2 diabetes mellitus rats. 1
- 73 Potential Antidiabetic Activities of Probiotic Strains, *L. acidophilus* and *L. bulgaricus* against Fructose-Fed Hyperglycemic Rats. **2019**, 10, 1419-1432 1

72	Relationship between thyroid function and nonalcoholic fatty liver disease in patients with chronic hepatitis B. <b>2019</b> , 27, 1100-1106		
71	Fisiopatología de la hepatitis C y diabetes mellitus. Hacia la cura de dos epidemias en el siglo XXI. <b>2019</b> , 34, 277-287		
70	Assessment of Hepatic Steatosis in Patients with Chronic Hepatitis B Using Fibroscan and its Relation to Insulin Resistance. <b>2019</b> , 9, 70-78		
69	Analysis of correlation between liver fat fraction and AST and ALT levels in overweight and obese children by using new magnetic resonance imaging technique. <b>2020</b> , 31, 156-162		3
68	Effect of Exercise Training on Spexin Level, Appetite, Lipid Accumulation Product, Visceral Adiposity Index, and Body Composition in Adults With Type 2 Diabetes. <b>2021</b> , 10998004211050596		2
67	Fabrication and Biological Assessment of Antidiabetic Mangostin Loaded Nanosponges: In Vitro, In Vivo, and In Silico Studies. <b>2021</b> , 26,		2
66	Association of cell death mechanisms and fibrosis in visceral white adipose tissue with pathological alterations in the liver of morbidly obese patients with NAFLD. <b>2021</b> , 10, 558-573		4
65	Plant Compounds for the Treatment of Diabetes, a Metabolic Disorder: NF- $\kappa$ B as a Therapeutic Target. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 4955-4969	3-3	3
64	Non alcoholic fatty liver disease and metabolic syndrome. <i>Hippokratia</i> , <b>2009</b> , 13, 9-19	0-4	295
63	Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome?. <b>2010</b> , 1, 27-33		12
62	Physical Activity is Related to Fatty Liver Marker in Obese Youth, Independently of Central Obesity or Cardiorespiratory Fitness. <i>Journal of Sports Science and Medicine</i> , <b>2015</b> , 14, 103-9	2-7	8
61	Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. <i>Current Opinion in Investigational Drugs</i> , <b>2009</b> , 10, 1049-60		91
60	Serum osteocalcin levels are inversely associated with the presence of nonalcoholic fatty liver disease in patients with coronary artery disease. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2015</b> , 8, 21435-41		3
59	Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , <b>2019</b> , 11, 45-63	3-4	129
58	Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus. <i>Journal of Diabetes Research</i> , <b>2021</b> , 2021, 7692447	3-9	
57	Cellgevity® attenuates liver disruption, oxidative stress and inflammation in STZ-diabetic male rats. <i>Scientific African</i> , <b>2021</b> , 14, e01055	1-7	0
56	GABA administration improves liver function and insulin resistance in offspring of type 2 diabetic rats. <i>Scientific Reports</i> , <b>2021</b> , 11, 23155	4-9	1
55	Interactions between insulin and exercise. <i>Biochemical Journal</i> , <b>2021</b> , 478, 3827-3846	3-8	0

54	Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk. <i>FEBS Journal</i> , <b>2021</b> ,	5.7	5
53	Metabolic Syndrome and Liver Cancer. <b>2021</b> , 1-19		0
52	Adiponectin alleviates nonalcoholic fatty liver injury via regulating oxidative stress in liver cells. <i>Minerva Medica</i> , <b>2020</b> ,	2.2	1
51	The effects of fish oil plus vitamin D intervention on non-alcoholic fatty liver disease: a randomized controlled trial.. <i>European Journal of Nutrition</i> , <b>2022</b> , 1	5.2	1
50	Cardiovascular Risk, Fatty Liver Disease, Glucose and Insulin Curve among prediabetes phenotypes in Peruvian population. <b>2022</b> , 100007		
49	Diabetes Medications and Risk of Hepatocellular Carcinoma.. <i>Hepatology</i> , <b>2022</b> ,	11.2	3
48	Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease.. <i>Metabolism: Clinical and Experimental</i> , <b>2022</b> , 130, 155179	12.7	0
47	The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE-/-FXR-/- Mice.. <i>Endocrinology and Metabolism</i> , <b>2021</b> , 36, 1243-1253	3.5	1
46	Hepatic Steatosis Is Associated with High White Blood Cell and Platelet Counts.. <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	0
45	Prevalence of Liver Cirrhosis based on the Metabolic Health and Weight Criteria: Report from the Korea National Health and Nutritional Health Examination Survey (KNANES) Data Analysis.. <i>Annals of Hepatology</i> , <b>2022</b> , 100721	3.1	0
44	Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	5
43	3,3',4,5'-Tetramethoxy-trans-stilbene Improves Insulin Resistance by Activating the IRS/PI3K/Akt Pathway and Inhibiting Oxidative Stress. <i>Current Issues in Molecular Biology</i> , <b>2022</b> , 44, 2175-2185	2.9	0
42	Lipids and nonalcoholic fatty liver disease. <b>2022</b> , 135-146		
41	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 631-639	1.6	18
40	The role of the liver in glucose and lipid metabolism in obesity. <b>2018</b> , 52, 1-6		
39	Metabolic Strategies in Healthcare: A New Era. <b>2022</b> , 13, 655		0
38	Beneficial Effects of Short-Term Growth Hormone Administration on Non-Alcoholic Fatty Liver Disease (NAFLD) in Obese Rats. <i>SSRN Electronic Journal</i> ,	1	
37	Triglyceride and Glucose Index as a Screening Tool for Nonalcoholic Liver Disease in Patients with Metabolic Syndrome. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 3043	5.1	0

36	Pituitary Tumor-Transforming Gene 1/Delta like Non-Canonical Notch Ligand 1 Signaling in Chronic Liver Diseases. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 6897	6.3	1
35	Association of triglyceride-glucose index with prognosis of COVID-19: a population-based study. <i>Journal of Infection and Public Health</i> , <b>2022</b> ,	7.4	0
34	The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
33	Metabolic Score for Insulin Resistance Is Inversely Related to Incident Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , <b>2022</b> , 14, 3039	6.7	0
32	Metabolic Syndrome and Liver Cancer. <b>2022</b> , 87-104		0
31	INCIDENCE OF HEPATIC DYSFUNCTION IN PATIENTS WITH DIABETES MELLITUS ADMITTED IN DARBHANGA MEDICAL COLLEGE AND HOSPITAL. 68-72		0
30	Transcriptomic analysis of the liver in aged laying hens with different eggshell strength. <b>2022</b> , 102217		0
29	Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study. 34,		0
28	Nonalcoholic fatty liver disease in children with obesity: observations from one clinical centre in the Western Pomerania region. 13,		0
27	Differences in Insulin Sensitivity, Secretion, and the Metabolic Clearance Rate of Glucose in Newly Diagnosed Type 2 Diabetes Mellitus Patients: The Influences of Body Mass Index and Fatty Liver. <b>2022</b> , 20, 451-458		0
26	Is Fasting Good When One Is at Risk of Liver Cancer?. <b>2022</b> , 14, 5084		0
25	Effect of a hexacyclic triterpenic acid from <i>Euscaphis japonica</i> on the oleic acid induced HepG2 cellular model of non-alcoholic fatty liver disease. <b>2022</b> , 31, 2209-2219		0
24	O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease. <b>2022</b> , 11, 3637		1
23	Emerging role for branched-chain amino acids metabolism in fibrosis. <b>2023</b> , 187, 106604		0
22	Mitochondria as a toxicological target for fungicides. <b>2023</b> , 493-526		0
21	The effect of aluminum on mitochondrial dysfunctions. <b>2023</b> , 205-234		0
20	Manifestation of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Different Dietary Mouse Models. 94-102		0
19	The Role of Senescence in NASH-Related HCC. <b>2022</b> ,		0

- 18 Human CYP2B6 produces oxylipins from polyunsaturated fatty acids and reduces diet-induced obesity. **2022**, 17, e0277053 ○
- 17 Triglyceride to high-density lipoprotein cholesterol ratio is an independent predictor of liver fibrosis among pediatrics non-alcoholic fatty liver disease. 13, ○
- 16 Association between Fasting and Postprandial Levels of Liver Enzymes with Metabolic Syndrome and Suspected Prediabetes in Prepubertal Children. **2023**, 24, 1090 ○
- 15 Using hyperhomocysteinemia and body composition to predict the risk of non-alcoholic fatty liver disease in healthcare workers. 13, ○
- 14 Enriched functional milk fat ameliorates glucose intolerance and triacylglycerol accumulation in skeletal muscle of rats fed high-fat diets. ○
- 13 Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria. **2023**, 12, 2126 ○
- 12 PPAR- $\beta$  signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. **2023**, 245, 108391 ○
- 11 Mini review: Hyperglycemia in ischemic stroke. **2022**, 7, 83 ○
- 10 Elevated alanine transaminase is nonlinearly associated with in-hospital death in ICU-admitted diabetic ketoacidosis patients. **2023**, 197, 110555 ○
- 9 Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis. **2023**, 23, ○
- 8 Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis: A Cross-Sectional Study. **2023**, 11, 723 ○
- 7 History of Gestational Diabetes and Incident Nonalcoholic Fatty Liver Disease: The Kangbuk Samsung Health Study. **2023**, Publish Ahead of Print, ○
- 6 Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Man's Land?. **2023**, 13, 857 ○
- 5 The crucial role and mechanism of insulin resistance in metabolic disease. 14, ○
- 4 Short-Term Growth Hormone Administration Mediates Hepatic Fatty Acid Uptake and De Novo Lipogenesis Gene Expression in Obese Rats. **2023**, 11, 1050 ○
- 3 Combinational administration of mesenchymal stem cell-derived exosomes and metformin reduces inflammatory responses in an in vitro model of insulin resistance in HepG2 cells. **2023**, e15489 ○
- 2 Visualizing Detection of Diabetic Liver Injury by a Biomarker-Activatable Probe via NIR-II Fluorescence Imaging. ○
- 1 Abnormal glucose tolerance in children: oral glucose tolerance test is fit-for-purpose. 235-245 ○

